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Biological profile of monocyte-
derived macrophages in coronary 
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The prevalence of a macrophage phenotype in atherosclerotic plaque may drive its progression and/or 
instability. Macrophages from coronary plaques are not available, and monocyte-derived macrophages 
(MDMs) are usually considered as a surrogate. We compared the MDM profile obtained from coronary 
artery disease (CAD) patients and healthy subjects, and we evaluated the association between CAD 
MDM profile and in vivo coronary plaque characteristics assessed by optical coherence tomography 
(OCT). At morphological analysis, MDMs of CAD patients had a higher prevalence of round than spindle 
cells, whereas in healthy subjects the prevalence of the two morphotypes was similar. Compared to 
healthy subjects, MDMs of CAD patients had reduced efferocytosis, lower transglutaminase-2, CD206 
and CD163 receptor levels, and higher tissue factor (TF) levels. At OCT, patients with a higher prevalence 
of round MDMs showed more frequently a lipid-rich plaque, a thin-cap fibroatheroma, a greater intra-
plaque macrophage accumulation, and a ruptured plaque. The MDM efferocytosis correlated with 
minimal lumen area, and TF levels in MDMs correlated with the presence of ruptured plaque. MDMs 
obtained from CAD patients are characterized by a morpho-phenotypic heterogeneity with a prevalence 
of round cells, showing pro-inflammatory and pro-thrombotic properties. The MDM profile allows 
identifying CAD patients at high risk.
Macrophages are heterogeneous in morphology and in function, and this heterogeneity has been well docu-
mented in different physiological and pathological conditions1–3. Also in experimental models and human ather-
osclerotic lesions, macrophages display morpho-phenotypic heterogeneity, with distinct subpopulations showing 
pro-inflammatory or reparative properties1,4–7. On these premises, it has been hypothesized that the prevalence of 
a specific macrophage phenotype may exert harmful or beneficial functions in the progression and/or destabili-
zation of the atherosclerotic plaque8,9. We have previously reported that monocytes isolated from healthy subjects 
and spontaneously differentiated into macrophages (MDMs) give rise to two dominant morphotypes coexisting 
in the same culture, namely round MDMs showing a non-inflammatory and reparative phenotype, and spindle 
MDMs exhibiting a pro-inflammatory profile10. To date, no information is available concerning the behavior 
of MDMs in patients with coronary artery disease (CAD). Therefore, an insight into the signature of MDMs 
obtained from patients with established CAD and their potential association with in vivo coronary plaque features 
might be of help in the understanding of the pro/anti-atherogenic potential of these cells.
Optical coherence tomography (OCT) provides high-resolution (10 µm) in vivo images of the atheroscle-
rotic plaque, allowing to acquire detailed information about its morphology and composition, including fibrous 
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cap thickness, lipid core, and macrophage accumulation. Combining plaque characterization at OCT investi-
gation with morpho-phenotypic data of MDMs may potentially provide a unique signature, in terms of MDM 
morpho-phenotype, for the identification of those plaques that are most likely to lead to a coronary event11–13.
Thus, in this study, we aimed at defining the antigenic and functional profile of the two dominant MDM 
morpho-phenotypes in acute myocardial infarction (AMI) and in stable CAD disease patients, as compared to 
healthy subjects. Moreover, we evaluated whether these in vitro information reflected the in vivo morphology 
features of coronary plaques along with their macrophage content in acute and chronic CAD patients undergoing 
OCT assessment.
Results
Clinical features of subjects. Of the 90 consecutive CAD patients (age 65 ± 12 years, males 71), 41 (46%) 
had a diagnosis of SA, whereas 49 (54%) of AMI (28 NSTEMI [57%] and 21 STEMI [43%]). Table 1 shows the 
clinical and angiographic data. For comparison, 25 subjects without CAD history were also included (age 49 ± 15 
years, males 10). OCT data concerning the investigated lesion of CAD patients according to their clinical pres-
entation (SA vs. AMI patients), are reported in Supplementary Table 1.
Biological profile of monocytes and MDMs. The distribution of classical and non-classical mono-
cyte subsets in healthy subjects and in CAD patients was not different (CD14++CD16− or classical monocytes: 
85.77 ± 8.58% and 85.07 ± 7.25%; P = 0.667; CD14+CD16++or non-classical monocytes: 4.62 ± 2.2% and 
3.69 ± 2.94%; P = 0.121, in healthy subjects and in CAD patients, respectively). An increase in intermediate 
monocytes (CD14++CD16−) count was detected in patients with CAD (10.46 ± 4.50% and 7.63 ± 1.95% in CAD 
patients and in healthy subjects, respectively; P = 0.001).
After in vitro differentiation of monocytes, MDMs positive for CD14 were 88.48 ± 5.64% and 87.80 ± 8.60% 
(P = 0.69) in healthy subjects and CAD patients, respectively. The CD14+CD16+ MDMs were 54.03 ± 19.84% and 
52.60 ± 21.19% (P = 0.92) in healthy subjects and CAD patients, respectively.
Morphological characterization of MDMs. MDMs of CAD patients had two predominant and different 
morphotypes, round and spindle. Differently from that observed in healthy subjects, who are characterized by a 
similar prevalence of these two morphotypes, in CAD patients, the prevalence of round MDMs was significantly 
higher than that of spindle or undefined MDMs (Fig. 1a,b). Furthermore, the frequency of round MDMs was 
particularly higher than that of spindle MDMs in AMI patients (Fig. 1 inset).
Both MDM morphotypes obtained from healthy subjects10 and CAD patients expressed the CD68 mac-
rophage marker (data not shown).
Efferocytic capacity of MDMs and levels of CD14 receptor and TG-2 protein. The efferocytic 
capacity of the MDMs of CAD patients, either SA or AMI (9.0 ± 1.96% and 9.90 ± 2.65% of MDMs that had 
engulfed apoptotic Jurkat T-cells, respectively; P = 0.21), was lower than that of healthy subjects’ MDMs (Fig. 2a).
Efferocytosis comprises the recognition, tethering, and uptake of apoptotic cells, and several factors are 
involved in these processes. CD14 is a member of a complex recognition system utilized by macrophages for the 
clearance of apoptotic lymphocytes14. However, we found that the count of CD14-positive MDMs (88.11 ± 5.46% 
and 90.26 ± 5.08% in healthy subjects and in CAD patients, respectively; P = 0.09) and the Mean Fluorescence 
Intensity for CD14 receptor (36.80 ± 23.40 and 38.80 ± 19.10 in healthy subjects and in CAD patients, respec-
tively; P = 0.73) was similar between healthy subjects and CAD patients.
Considering the relevant role of transglutaminase (TG)-2 in the formation of an efficient phagocyte portal in 
macrophages15, we verified whether changes in the expression of this protein may be responsible for the impaired 
efferocytosis of CAD MDMs. MDMs obtained from CAD patients had markedly lower levels of TG-2 than those 
obtained from healthy subjects (Fig. 2b). Of note, in healthy subjects, TG-2 levels were higher in round MDMs 
(Fig. 2c,d), the morphotype with a greater capacity to bind/uptake apoptotic cells10. In contrast, in CAD patients, 
TG-2 levels were similar in round and spindle MDMs, suggesting a potential contribution of this protein in the 
reduction of the apoptotic cell clearance detected in these patients (Fig. 2c,d).
Levels of CD206 and CD163 receptors. The mannose receptor CD206 and the haptoglobin/hemoglobin 
scavenger receptor CD163 have been associated with the non-inflammatory, anti-atherogenic macrophage phe-
notype16,17. A significant decrease of CD206 levels in both MDM morphotypes has been observed in NSTEMI 
and STEMI patients as compared to healthy subjects (Fig. 3a,b). In addition, CD163 levels were significantly 
lower only in the round MDM morphotype of NSTEMI and STEMI patients when compared to healthy subjects 
(Fig. 3c,d).
Tissue factor levels and thrombin generation. Tissue factor (TF) represent the main cellular activator 
of the blood coagulation cascade, allowing the thrombin generation. The MDMs of CAD patients had a signifi-
cantly greater TF expression than those of healthy subjects (Fig. 4a). Moreover, a significantly greater TF fluores-
cence intensity was detected in both MDM morphotypes of CAD patients when compared to their counterparts 
in healthy subjects (Fig. 4b). This enhanced antigenic expression of TF displayed a functional consequence in 
thrombin generation. Indeed, the lag time and the time to peak in thrombin generation were lower in MDMs of 
CAD patients as compared to healthy subjects. In contrast, the peak of thrombin generation and the endogenous 
thrombin potential (ETP) did not change (Fig. 4c). Furthermore, an increasing gradient in TF levels going from 
MDMs (spindle and round) of healthy subjects to MDMs of SA, NSTEMI, and STEMI patients was observed. Of 
note, the highest TF levels were detected in both morphotypes of STEMI patients (Fig. 4d), suggesting a potential 
greater MDM contribution to thrombus formation in patients experiencing an acute coronary event.
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Matrix metalloproteinase-9 activity. MDMs showed a progressive matrix metalloproteinase-9 (MMP-
9) activity increase in SA or AMI patients, reaching a maximum in STEMI patients, as compared with healthy 
subjects (Fig. 5), suggesting a greater in vivo potential for MDMs to induce plaque vulnerability or rupture of the 
fibrous cap.
MDM profile, angiographic analyses, and OCT plaque features. Representative OCT images of cor-
onary atherosclerotic plaques are showed in Fig. 6.
The prevalence of in vitro round MDMs was significantly higher in patients presenting a thin-cap fibroath-
eroma (TCFA), a lipid plaque, a ruptured plaque, and a thrombus (Fig. 7a–d). The prevalence of round MDMs 
Variables SA, N = 41 AMI, N = 49 P value
Demographics
Age (years) 68 ± 9 62 ± 12 0.02
Male sex, n (%) 33 (81) 38 (77) 0.73
BMI (kg/m²) 28.6 ± 3.1 29.2 ± 4.1 0.45
Clinical characteristics
Current smoker, n (%) 26 (63) 30 (61) 0.83
Diabetes mellitus, n (%) 11 (27) 23 (47) 0.05
Dyslipidemia, n (%) 21 (51) 26 (49) 0.86
Hypertension, n (%) 24 (58) 27 (55) 0.74
Family history of CAD, n (%) 19 (46) 27 (55) 0.41
LVEF (%) 55 ± 7 47 ± 6 0.45
Laboratory data
WBC (×109/l) 8.77 ± 3.04 9.21 ± 3.60 0.53
RBC (×1012/l) 4.62 ± 0.70 5.44 ± 3.59 0.15
Neutrophil count (×109/l) 6.41 ± 3.21 5.96 ± 2.82 0.48
Lymphocyte count (×109/l) 2.03 ± 0.83 1.95 ± 0.82 0.62
Eosinophil count (×109/l) 0.37 ± 1.14 0.36 ± 1.08 0.94
Monocyte count (×109/l) 0.63 ± 0.23 0.60 ± 0.25 0.56
Basophil count (×109/l) 0.007 ± 0.03 0.006 ± 0.02 0.78
Platelets (×109/l) 220 ± 74 227 ± 74 0.67
hs-CRP (mg/l) 2.10 (1.40–3.20) 13.20 (5.00–26.00) 0.0001†
Creatinine (mg/dl) 1.02 ± 0.37 0.96 ± 0.31 0.09
Glycaemia (mg/dl) 124 ± 27 131 ± 36 0.33
Total cholesterol (mg/dl) 170 ± 35 206 ± 45 0.0001
LDL (mg/dl) 97 ± 26 129 ± 41 0.0001
HDL (mg/dl) 50 ± 15 43 ± 10 0.009
Triglycerides (mg/dl) 122 ± 55 163 ± 63 0.002
Peak TnI (μg/dl) 0.001 (0.001–0.002) 12.30 (1.40–34.60) 0.0001†
Peak CK-MB (μg/dl) 2.10 (1.60–3.42) 85.40 (13.20–213.00) 0.0001†
Angiographic data
Culprit or treated vessel, n (%) 0.03*
LAD 16 (39) 33 (67)
LCX 7 (17) 5 (10)
RCA 18 (44) 11 (23)
Multivessel disease, n (%) 28 (68) 23 (47) 0.04
Admission therapy
ASA, n (%) 14 (34) 20 (29) 0.65
Beta-Blockers, n (%) 12 (29) 14 (29) 0.94
ACE-inhibitors, n (%) 21 (51) 11 (22) 0.004
Statins, n (%) 17 (41) 14 (29) 0.2
Table 1. Baseline clinical, laboratory and angiographic characteristics of coronary artery disease patients 
according to their clinical presentation. Data are expressed as mean ± SD or median and interquartile range. P 
value: Wilcoxon test for quantitative variables. *Fisher test, †Kruskal-Wallis test. SA, stable angina; AMI, acute 
myocardial infarction; CAD, coronary artery disease; BMI, body-mass index; LVEF, left ventricular ejection 
fraction; WBC, white blood cells; RBC, red blood cells; LDL, low-density lipoprotein; HDL, high-density 
lipoprotein; hs-CRP, high-sensitive C-reactive protein; TnI, troponin-I; CK-MB, Creatine phosphokinase-MB; 
LAD, left anterior descending; LCX, left circumflex; RCA, right coronary artery; ASA, aspirin; ACE-inhibitors, 
angiotensin-converting-enzyme inhibitors.
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inversely correlated with plaque cap thickness (R = −0.65; P < 0.0001), and it positively correlated with the max-
imum lipid quadrant (R = 0.36; P = 0.04). The quantification of CAD severity can be captured using coronary 
angiography, and several scoring systems were developed to assess it. At angiographic analysis of CAD severity, 
round MDMs tended to correlate with the Bogaty extent (R = 0.35; P = 0.08) and severity (R = 0.37; P = 0.07) 
scores, and they significantly correlated with the Sullivan score (R = 0.57, P = 0.002). Moreover, the intra-plaque 
macrophages identification was associated with a higher round MDMs prevalence (Fig. 7e), and the latter posi-
tively correlated with normalized standard deviation (NSD) (R = 0.66; P < 0.001; Fig. 7f).
Moreover, the MDM efferocytic ability positively correlated with the minimal lumen area (MLA) (R = 0.49; 
P = 0.013), and it tended to inversely correlate with stenosis plaque percentage (R = 0.35; P = 0.08). In addition, 
when evaluating indexes of angiographic CAD severity, MDM efferocytic capacity inversely correlated with 
the Bogaty extent (R = −0.43; P = 0.04) and severity (R = −0.41; P = 0.05) scores, and with the Sullivan score 
(R = −0.47; P = 0.04).
However, TG-2 in round MDMs and in spindle MDMs did not correlate with MLA (P = 0.50; P = 0.21) nor 
with stenosis plaque percentage (P = 0.91; P = 0.32).
TF levels in round and spindle in vitro obtained MDMs positively correlated with the in vivo detection of a 
ruptured plaque (R = 0.36, P = 0.05 and R = 0.47, P = 0.01, respectively). Additionally, TF expression in both 
MDM morphotypes positively correlated with the presence of thrombus (R = 0.36, P = 0.05 and R = 0.47, 
P = 0.01, respectively). Finally, TF levels in round and spindle MDMs positively correlated with the intra-plaque 
macrophages presence (R = 0.57, P = 0.001 and R = 0.64, P < 0.001, respectively), and they tended to positively 
correlate with NSD (P = 0.08 and P = 0.11).
All these observations may suggest that the profile of MDMs may be related to high-risk features of the coro-
nary plaque morphology and activity.
Discussion
In this report, we show for the first time that the spontaneous in vitro differentiation of monocytes into MDMs of 
CAD patients results in a higher prevalence of round MDMs, having a lower efferocytic capacity and an enhanced 
thrombin generation capacity, as compared to healthy subjects. Additionally, in CAD patients, the propensity 
of monocytes to differentiate into round MDMs is associated with the detection of vulnerable and/or ruptured 
plaque, as assessed by OCT intracoronary imaging.
Studies on tissue-resident macrophages are very challenging due to the difficulties in macrophage extraction 
and tissue availability. Moreover, coronary atherosclerotic plaque is a compartment not easily accessible, and 
Figure 1. MDM morphology and frequency. (a and b) Representative image (AxioVert 200 M, Zeiss, 200× 
original magnification) of MDMs obtained from healthy subjects and CAD patients (top); frequency in round, 
spindle, and undefined MDMs in healthy subjects and in CAD patients (bottom). Inset, frequency in round, 
spindle, and undefined MDMs in stable angina (SA) and acute myocardial infarction (AMI) patients. Data are 
expressed as the mean ± SD, and they derive from independent cultures obtained from 25 healthy subjects and 
50 CAD patients (19 SA and 31 AMI patients). *P < 0.001 round versus spindle and versus undefined MDMs, 
**P < 0.0001 round versus spindle and versus undefined MDMs.
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macrophages obtained from a spontaneous differentiation of circulating monocytes may be considered a good 
surrogate. By investigating MDM morpho-phenotypes in the different CAD clinical presentation, we found that, 
differently from healthy subjects, who are characterized by a similar frequency of spindle and round cells10, CAD 
patients have mostly round MDMs. This was unexpected, as round MDMs in healthy subjects proved to exhibit 
anti-inflammatory properties. However, the differences between CAD patients and healthy subjects in terms of 
MDMs are not confined to morphology, but also reflected in different antigenic and functional profiles. In par-
ticular, despite the prevalence of round cells, MDMs of CAD patients were characterized by an anti-inflammatory 
properties reduction as compared to MDMs of healthy subjects, as supported by their lower levels of CD206 and 
Figure 2. Efferocytosis and TG-2 levels in MDMs. (a) MDMs were co-cultured with early apoptotic Jurkat 
T-cells for 30 minutes, and the uptake was assessed by flow cytometry. Data are expressed as the percentage of 
MDMs that had engulfed carboxy fluoroscein diacetate succinimidyl ester (CSFE)-stained Jurkat apoptotic cells, 
and they derive from independent cultures obtained from 25 healthy subjects and 50 CAD patients. (b) TG-2 
was detected by western blot analysis. β-actin was used as a control of protein loading. Densitometry is shown in 
the bar graph. Data are expressed as mean ± SD, and they derive from MDMs obtained from 5 healthy subjects 
and 10 CAD patients. (c) Representative images (400× original magnification) and (d) quantitative analysis of 
TG-2 in round and spindle MDMs obtained from healthy subjects and CAD patients. Nuclei were visualized by 
Hoechst 33258. Data derive from independent cultures obtained from 10 healthy subjects and 30 CAD patients. 
*P < 0.05, **P < 0.005. Full blots are shown in Supplementary Fig. 1.
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CD163, both markers of the anti-inflammatory macrophage phenotype16,17. Indeed, it has been shown that mac-
rophages expressing high levels of CD206 and CD163 had a reduced pro-inflammatory cytokine production18; 
and, accordingly, a high expression of CD206 was peculiar of phagocytic macrophages19. Therefore, as plaque 
development may originate also from inadequate anti-inflammatory responses, the macrophage polarization 
imbalance may play a critical role in plaque formation20,21. Notably, macrophage phenotype is affected by the 
surrounding microenvironment and by cell-cell interactions. Indeed, the interaction between CD40L (Ligand), 
expressed on T lymphocytes surface, and CD40, highly expressed in pro-inflammatory macrophages22, induces 
the expression of adhesion molecules, and the release of matrix metalloproteinases and pro-inflammatory 
cytokines, promoting monocyte recruitment and plaque progression23. Thus, the imbalance in the inflammatory 
response in atherosclerotic plaques might be supported by a loss of anti-inflammatory properties of the round 
MDMs detected in CAD patients. To further investigate this observation, we evaluated the efferocytic capacity of 
MDMs and correlated it with angiographic and OCT CAD burden. Interestingly, we found a significant reduction 
of the efferocytic ability in the MDMs of CAD patients as compared to healthy subjects, and, in our cohort of 
Figure 3. CD206 and CD163 levels in MDMs. (a) Representative images (400× original magnification) of 
CD206 in MDMs obtained from healthy subjects and CAD patients. (b) Quantitative analysis of CD206 levels in 
MDM morphotypes of healthy subjects and patients. (c) Representative images (400× original magnification) 
of CD163 in MDMs obtained from healthy subjects and CAD patients. (d) Quantitative analysis of CD163 levels 
in MDM morphotypes of healthy subjects and patients. Nuclei were visualized by Hoechst 33258. Data derive 
from independent cultures obtained from 3 healthy subjects, 3 SA patients, 3 NSTEMI patients, and 3 STEMI 
patients. *P < 0.05.
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CAD patients, coronary angiographic analyses demonstrated that, the lower was the MDM efferocytic capacity, 
the more severe and extensive was the coronary atherosclerotic burden. A similar behavior was observed when 
considering MLA and stenosis grade of the investigated lesion by means of OCT. It is well known that, at coro-
nary plaque level, apoptotic cell death and efferocytic rates are strongly related to atherosclerotic lesion stage24. 
The apoptotic cell clearance enhances the resolution of the ongoing inflammatory process, by modulating several 
and critical inflammatory pathways, including IL-10 and TGF-β release, and promoting phagocyte survival25–27. 
Thus, even a small reduction in efferocytic ability may have relevant clinical implications. The reduced efferocy-
tosis detected in CAD MDMs did not depend on the binding of apoptotic cell mediated by the CD14 receptor, 
but it was related to the expression of TG-2, a protein-cross-linking enzyme involved in an efficient phagocytic 
portal formation15. These observations further confirm the presence of significant functional differences of CAD 
MDMs, as compared to healthy subjects, that may be involved in atherosclerosis initiation and progression and 
potentially in its complications. This may pave the way to pharmacological modulation studies aimed at limiting 
Figure 4. TF levels and thrombin generation in MDMs. (a) TF was detected by western blotting. β-actin was 
used as a control of protein loading. Densitometry is shown in the bar graph. Data are expressed as mean ± SD 
and derive from MDMs obtained from 12 healthy subjects and 14 CAD patients. (b) Representative images 
(400× original magnification) of TF in MDMs obtained from healthy subjects and CAD patients. Nuclei were 
visualized by Hoechst 33258. Data derive from independent cultures obtained from 10 healthy subjects and 30 
CAD patients. (c) Thrombin generation parameters measured in MDMs obtained from 16 healthy subjects and 
20 CAD patients. (d) Quantitative analysis of TF levels in MDM morphotypes of healthy subjects and patients. 
Data derive from independent cultures obtained from 10 healthy subjects, 10 SA patients, 10 NSTEMI patients, 
and 10 STEMI patients. *P < 0.05, **P < 0.005. Full blots are shown in Supplementary Fig. 2.
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progression and improving stabilization of coronary atherosclerosis, by a direct targeting of specific MDM sub-
populations. Of note, recently published studies found that antibodies blocking CD47, a key anti-phagocytic 
molecule, could restore phagocytosis and prevent atherosclerosis28.
Macrophages are intrinsically linked not only to atherosclerotic disease progression but also to disease 
activity. Indeed, the amount of monocyte-macrophages infiltrating the plaque and their detection at plaque 
rupture-sensitive sites are associated to plaque vulnerability29,30. Interestingly, we found that the propensity of 
circulating monocytes to differentiate into round MDMs in CAD patients was associated with a vulnerable plaque 
presence and with a ruptured plaque, as evaluated by OCT analyses. The risk of an acute coronary event is related 
to the composition and activity of the plaque, and inflammation is crucial for its instability31–33. Our observa-
tion could imply that round MDMs in CAD patients may reduce lesion integrity and increase the likelihood of 
an acute myocardial infarction. Indeed, the presence of a thinner fibrous cap, a larger lipid core, and a greater 
macrophage content were more frequently detected in CAD patients with a higher prevalence of in vitro round 
MDMs. Thus, although our data provide initial observational insights on the potential association between vul-
nerable coronary plaques and round MDMs in CAD patients, this morpho-type might represent a tool able to 
recognize high-risk patients of developing an acute myocardial infarction. Yet, future mechanistic studies and/or 
transcriptomic investigations, combined with the in vivo analysis of coronary atherosclerotic plaques, are needed 
in order to support our findings, to identify the involved signal transduction, and to explore the contribution of 
an intrinsic differentiation program or of environmental imprinting of monocytes, in determining the diversity 
of MDMs34.
Finally, it is known that plaque macrophage accumulation may favor both rupture of fibrous cap, due to 
pro-inflammatory cytokines and proteolytic enzymes secretion, and thrombus formation, due to TF release35. It 
has been shown that circulating TF may potentiate the thrombogenic stimulus and upregulate the inflammatory 
response36,37. TF is synthetized by macrophage-derived foam cells in atherosclerotic plaques, and its expression is 
increased in lipid-rich plaques38,39. In our report, the MDMs obtained from AMI patients showed a higher TF flu-
orescence than the MDMs of healthy subjects, with a peak in STEMI patients. In addition, we found that TF levels 
in spindle and in round MDMs positively correlated with the OCT detection of a ruptured plaque and of thrombi. 
Accordingly, it has been documented that TF levels were higher in atheroma of patients with acute coronary 
syndrome than with SA40. Then, TF expression may enhance the severity of acute coronary thrombosis, further 
Figure 5. MMP-9 activity. MDMs were incubated overnight in medium containing 0.2% fatty-acid-free 
albumin. The activity of MMP-9 secreted by MDMs was evaluated by the BiotrakTM activity assay system. Data 
are expressed as mean ± SD and derive from independent cultures obtained from 9 healthy subjects, 9 SA 
patients, and 18 AMI (9 NSTEMI and 9 STEMI) patients. *P < 0.05 vs. healthy subjects.
Figure 6. Representative OCT images of coronary atherosclerotic plaque. (a) Stable fibrous coronary plaque. 
(b) High-risk thin-cap fibroatheroma (white arrows). (c) Coronary rupture plaque with macrophage infiltration 
(white arrows).
9Scientific RepoRts |          (2019) 9:8680  | https://doi.org/10.1038/s41598-019-44847-3
www.nature.com/scientificreportswww.nature.com/scientificreports/
highlighting the functional differences between the MDMs of CAD patients and those of healthy subjects. Indeed, 
round MDMs in CAD patients seem to lose their anti-inflammatory properties, and to acquire pro-thrombotic 
features, potentially contributing, at least in part, to acute coronary event initiation and severity. The mechanisms 
underlying this observation cannot be deduced from our study; yet, this study shows a peculiar phenotype of 
round MDMs in CAD patients that may potentially affect the inflammatory status and the pathogenesis of coro-
nary atherosclerosis and atherothombosis.
Our findings might have some potential clinical implications. Although this is an observational study and 
a cause-effect relationship cannot be established, the definition of an MDM profile may help to predict CAD 
burden and coronary plaque composition, also contributing to the differentiation between stable and unstable 
plaques. Moreover, the development of therapies that blunt macrophage cytotoxicity, plaque growth, and dest-
abilizing functions and enhance their natural reparative properties, may represent a new approach to curtail 
macrophage-mediated injury, limit coronary stenosis progression and enhance plaque stability41, the two most 
important aims when counteracting coronary atherosclerosis. Of interest, emerging evidences suggest the pos-
sibility of pharmacologically modulating the functions of macrophages42–44. In particular, our findings, if con-
firmed in larger study populations, may pave the way to novel diagnostic tools, able to early identify patients at 
Figure 7. OCT plaque features and frequency of round MDM morphotype. Correlation between round 
MDM morphotype and (a) thin-cap fibroatheroma (TCFA), (b) plaque lipid content, (c) fibrous cap integrity, 
(d) presence of thrombi, (e) presence of intra-plaque macrophages, and (f) macrophage normalized standard 
deviation (NSD), detected by means OCT in in vivo plaque. *P < 0.02, **P < 0.002, ***P < 0.0005, #P < 0.0001.
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high risk of severe CAD and/or of atherothrombosis. Further, our observations may be useful to develop novel 
therapies able to manipulate macrophage morpho-phenotype, with the ultimate goal of reducing CAD burden 
and first or recurrent acute cardiovascular events.
Some limitations warrant mention. First, the small sample size of our study limits the general applicability of 
our findings. Second, even if the macrophage heterogeneity has been documented in tissues, these macrophage 
phenotypes may not correspond to phenotypes generated in vitro. Indeed, in atherosclerotic lesions, macrophages 
respond to several environmental stimuli, such as cytokines and modified lipids, and they interact with other 
cells, including erythrocytes, lymphocytes, and platelets45–47, potentially modifying their phenotypes. Thus, an 
assessment of monocyte functions and of their differentiation process via interaction with other cells, such as 
lymphocytes and platelets, and in relation to progenitors and stem cells, is needed. Third, our in vitro model 
may be used as a representative model of tissue macrophages10,48,49, however, the lack of cell turnover and of 
tissue-specific matrix proteins, are crucial in tissue macrophage behavior. Fourth, OCT imaging is a suboptimal 
reflection of true histology, mainly for macrophage infiltration50,51.
In conclusion, we demonstrated that the MDMs of CAD patients, as compared to healthy subjects, show a 
peculiar morpho-phenotype profile, which is characterized by a predominance of round MDMs, with reduced 
anti-inflammatory properties and a higher propensity for thrombogenicity than those of healthy subjects. 
Notably, this specific profile is associated with the detection of high-risk and rupture-prone coronary plaques, at 
OCT investigation. Assessing the functional features of macrophage phenotypes may allow to shed lights on their 
contribution to coronary atherosclerosis, thus providing novel diagnostic, therapeutic, and, more importantly, 
preventative regimens for CAD.
Methods
Study design. The study was carried out at Centro Cardiologico Monzino, Milan, Italy. Ninety consecutive 
CAD patients undergoing coronary angiography due to stable angina (SA) or AMI, as their first ischemic heart 
disease event, and showing obstructive atherosclerosis (>50% diameter stenosis by visual estimate) were enrolled. 
Twenty-five healthy subjects, with neither history of CAD, nor cardiovascular risk factors, nor inflammatory dis-
orders, and specifically not taking any cardiovascular therapy, were recruited as control group.
In the initial 40 CAD patients, we performed the characterization of MDMs of CAD patients, and we com-
pared these data to those obtained in healthy subjects. Subsequently, we evaluated the association between this 
profile and CAD clinical presentation, and we also assessed plaque composition in 50 patients undergoing OCT 
evaluation.
The study was approved by the institutional Ethic Committee (Comitato Etico IRCCS-Istituto Europeo di 
Oncologia e Centro Cardiologico Monzino), and it was performed according to the Declaration of Helsinki. All 
the study subjects provided written informed consent at the time of enrollment.
Culture of MDMs. MDMs were obtained from a differentiation of monocytes isolated from venous blood 
of CAD patients and healthy subjects as described10. Briefly, mononuclear cells were obtained by density centrif-
ugation on Ficoll-Paque (GE Healthcare, EuroClone, Milan, Italy) and plated (2 × 106/mL) in 35 mm well plates 
(PrimariaTM, Falcon, Sacco S.r.l, Como, Italy). After 90 minutes, non-adherent cells were removed, and adherent 
monocytes were cultured over 7 days in Medium 199 (Lonza, EuroClone, Milan, Italy) supplemented with 2 mM 
L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, and 10% autologous serum freshly obtained from 
blood clotted for 2 hours at 37 °C. Medium was not replaced throughout the culture period. The morphology of 
MDM was inspected by phase contrast microscopy (AxioVert 200 M, Zeiss, Milan, Italy) at 20× or 40× magnifi-
cation. MDMs were defined spindle when a length >70 µm and a width <30 µm were detected, and round when 
width and length were similar and >35–40 µm. Cells of morphology and/or dimension that did not meet the 
above criteria were classified as undefined10.
Flow cytometric analysis of monocytes and MDMs. Monocyte subsets were analyzed in 100 μl of 
whole blood collected from all participants. Adherent MDMs were detached with trypsin.
Cells were stained for 10 min with monoclonal mouse anti-human CD14 APC-conjugated and CD16 
FITC-conjugated antibodies (BD Biosciences, Milan, Italy) and analyzed using flow cytometry52. Data were ana-
lyzed using CellQuest analysis software (Becton-Dickinson, Oxford, UK).
Apoptosis of Jurkat T-cells. Jurkat T-cell line, clone E6-1 (ATCC), was purchased from LGC Standards 
S.r.l. (Milan, Italy), and cultured in RPMI 1640 supplemented with 10% fetal calf serum (Lonza, EuroClone) 
and 26 mM HEPES. Early apoptosis was induced by incubating cells (4 × 106 cells/ml) for 2 hours in serum-free 
RPMI 1640 with 10 µM etoposide (Sigma Aldrich, Milan, Italy)53. The extent of apoptosis was evaluated by flow 
cytometry using annexin V PE (BD Biosciences), according to the manufacturer’s instructions, and 20,000/sam-
ple events were acquired.
Efferocytosis assay. Before the induction of apoptosis, Jurkat T-cells were stained with 5 µM carboxyfluo-
rescein diacetate succinimidyl ester (CFSE, Life Technologies, Milan, Italy) for 30 minutes at 37 °C. CSFE-labeled 
apoptotic cells (1 × 106 cells/ml) were co-cultured with MDMs (2:1 ratio) for 30 minutes. Non-ingested cells 
were removed. Adherent MDMs were detached with trypsin, incubated with APC anti-human CD14 antibody 
(BD Biosciences), or isotype-matched irrelevant antibody, for 15 minutes at room temperature (RT), and ana-
lyzed by flow cytometry. 10,000 events were acquired, and the data were analyzed using CellQuest software 
(Becton-Dickinson). Data are expressed as percentage of CD14-positive MDMs that had binding/engulfed 
CSFE-labeled apoptotic Jurkat T-cells54.
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Western blot analysis. Western blotting was performed as previously described55. Nitrocellulose blotting 
membranes were incubated with primary antibodies directed against TG-2, (Cell Signaling, EuroClone, Milan, 
Italy), or TF (American Diagnostica, Sekisui Diagnostics, Cabru, Milan, Italy). After incubation with a horserad-
ish peroxidase-conjugated secondary antibody (Jackson ImmunoResearch Labs Inc., Li StarFISH, Milan, Italy), 
the immunoreactive protein bands were detected by chemiluminescence. β-actin was used as loading control.
Thrombin generation measurement. MDMs were lysed in 15 mM octyl-β-D-glycopiranoside (Sigma 
Aldrich) as previously described56. One µg lysed cells (20 µl) were mixed with 10 µl of 25 mM HEPES 
buffered-saline and 20 µl of platelet-poor plasma. Thrombin generation was triggered by the addition of fluoro-
genic substrate Z-Gly-Gly-Arg-AMC (Stago Italia S.R.L. Unipersonale, Milan, Italy) in the presence of CaCl2 and 
measured for 60 minutes using the Calibrated Automated Thrombogram® assay (Thrombinoscope BV, 
Maastricht, the Netherlands). The lag-time, peak of thrombin generation, ETP, and velocity index of propagation 
phase (VelIndex) were calculated using Thrombinoscope software (Thrombinoscope BV).
Immunofluorescence staining. MDMs were fixed (2% para-formaldehyde, for 20 min at RT), and 
non-specific reactive sites were blocked with 5% bovine serum albumin (BSA) solution containing 0.1% sapo-
nin (30 minutes, RT)10. MDMs were incubated overnight at 4 °C with antibodies directed toward CD68 (Dako 
Italia S.p.A., Milan, Italy), TG-2, TF, CD206 (Abcam, Prodotti Gianni, Milan, Italy), CD163 (AbD serotec, Space 
Import-Export, Milan, Italy). Detection was performed with appropriate Alexa Fluor 488 (60 minutes, RT) (Life 
Technologies). Negative control were performed in parallel by omitting the primary antibodies.
Quantitative fluorescent image analysis. Digital images were taken on an AxioObserver.Z1 microscope 
connected to a camera, and processed using the AxioVision 4.7 (Zeiss) software. Fluorescence intensity (densi-
tometric sum of gray) was quantified, as an index of the amount of the protein investigated10. Data are expressed 
as log median of fluorescence intensity/μm2 and interquartile range for each MDM morphotype, subtracting the 
negative control value. Multiple fields of view (at least three fields, 400× magnification) were taken for each cul-
ture. Means derive from 10 independent cultures obtained from different donors.
Matrix metalloproteinase-9 activity. MDMs were washed, and fresh medium containing 0.2% fatty acid 
free albumin was added. After overnight incubation, supernatant was collected and centrifuged, and the activity 
of MMP-9 secreted by MDMs was evaluated by the BiotrakTM activity assay system (Amersham, GE Healthcare, 
Milan, Italy).
Angiographic analyses. Angiographic analyses for the evaluation of CAD severity and extent were focused 
on the assessment of the Bogaty score57 and the Sullivan extent score58.
OCT image analysis. Culprit lesion, in AMI patients, was identified by angiography, electrocardiographic 
T-wave or ST-segment modifications, and/or regional wall motion abnormalities at echocardiogram. In SA 
patients, OCT analysis was performed at the MLA site. Frequency domain OCT (FD-OCT) images were acquired 
by a commercially available system (C7 System, LightLab Imaging Inc/St Jude Medical, Westford, MA) connected 
to an OCT catheter (C7 Dragonfly; LightLab Imaging Inc/St Jude Medical), which was advanced to the culprit 
lesion. All images were digitally recorded and stored, and every single frame (0.2 mm) was analyzed by two inde-
pendent investigators from an OCT core lab, who were blinded to clinical and laboratory values (Institute of 
Cardiology, Catholic University of the Sacred Heart, Policlinico Gemelli, Rome, Italy)59.
At the MLA site or at culprit lesion, respectively in SA and AMI patients, the analysis was targeted on plaque 
characterization (calcified, fibrous, or lipid plaques), presence of plaque rupture, measurement of fibrous cap 
thickness, and presence of intracoronary thrombi and intra-plaque microchannels, as previously described11–13. 
When a plaque contained two or more lipid-containing quadrants, it was considered a lipid-rich plaque, and the 
lipid arc and the cap thickness were measured. TCFA was defined as a lipid-rich plaque with a fibrous cap thick-
ness of ≤65 µm60.
OCT macrophage analysis. The presence of macrophage infiltration (MØI) in the lesions analyzed by 
OCT was assessed as previously reported59. Briefly, macrophages were qualitatively identified on raw OCT data 
within a 300 × 125 µm2 (lateral × axial) region of interest (ROI), according to the International Working Group 
for Intravascular Optical Coherence Tomography (IWG-IVOCT) Consensus standards12.
Macrophages were visualized as signal-rich, distinct, or confluent punctate regions exceeding the intensity 
of background speckle noise and generating a backward shadowing. For caps having a thickness <125 µm2, the 
depth of the ROI was matched to the cap thickness. Median filtering was performed with a 3 × 3 square kernel 
to remove speckle noise. In plaques with MØI, quantitative evaluation of macrophage content was obtained by 
measuring the NSD known to have a high degree of positive correlation with histological measurements of mac-
rophage content, by using a dedicated software provided by S. Jude Medical13,61. NSD was measured for each 
pixel within each cap using a 125 µm2 window centered at the pixel location: NSD (x, y) = [σ (x, y)125 µm2/
(Smax-Smin)] × 100, where NSD (x, y) is the normalized standard deviation of the OCT signal at pixel location 
(x, y), Smax is the maximum OCT image value, and Smin is the minimum OCT image value. Pixels within the 
(125 × 125) µm2 window that did not overlap with the segmented cap were excluded13.
Statistical analysis. The distribution of continuous variables was assessed by visual inspection of frequency 
histograms and with the use of the Shapiro-Wilk test. Continuous variables were expressed as mean ± stand-
ard deviation (SD) or median with interquartile range, if they followed a normal or non-normal distribution, 
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respectively. Continuous variables were compared with unpaired t-test or Mann-Whitney U-test, whereas cate-
gorical variables were compared using the Chi square test or Fisher’s exact test, as appropriate. Paired-group com-
parison was performed using the paired t-test or Wilcoxon test, as appropriate. Unpaired t-test or Mann-Whitney 
U-test were used for the comparison of continuous variables between groups; continuous variables among groups 
were compared with ANOVA or Kruskal-Wallis test, and Bonferroni’s correction for multiple comparison was 
applied and the Bonferroni-adjusted-P-value was reported. Correlations between variables were performed using 
the Pearson test or the Spearman’s rank test, as appropriate. Intra-observer and inter-observer variability in the 
analysis of MØI in the fibrous cap were assessed by Kappa measure of agreement. Regarding the evaluation of 
MØI, Kappa measures of agreement for intra-observer and inter-observer variability were 0.89 (P < 0.0001) and 
0.94 (P < 0.001), respectively. All performed analyses were adjusted for age and sex.
All tests were two-sided. A P value < 0.05 was considered to indicate statistical significance. All calculations 
were computed with the aid of the SAS software package (Version 9.2; SAS Institute Inc., Cary, NC).
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